Non-linearity of Parkinson’s disease progression: implications for sample size calculations in clinical trials

Author:

Guimaraes Paulo1,Kieburtz Karl2,Goetz Christopher G3,Elm Jordan J,Palesch Yuko Y,Huang Peng1,Ravina Bernard4,Tanner Caroline M5,Tilley Barbara C1

Affiliation:

1. Dept of Biostatistics, Bioinformatics & Epidemiology, Medical University of South Carolina, Charleston, SC, USA

2. Dept of Neurology, University of Rochester, Clinical Trials Coordination Center, Rochester, NY, USA

3. Dept of Neurological Sciences, Rush University’s Medical Center, Chicago, IL, USA

4. NINDS, National Institutes of Health, Neuroscience Center, Bethesda, MD, USA

5. The Parkinson’s Institute, 1170 Morse Avenue, Sunnyvale CA, USA

Abstract

Background Estimation of sample size for long-term studies of neuroprotection in Parkinson’s disease requires information on expected clinical decline. Values may be obtained by analyzing existing long-term data sets or by prediction models of clinical decline applied to available data from shorter-term trials. The most commonly used measure to track clinical decline is the Unified Parkinson’s Disease Rating Scale (UPDRS) but this measure is also affected by symptomatic therapy. Models can help better understand behavior of the UPDRS after initiation of symptomatic therapy when scores will improve and eventually start deteriorating again. Purpose To understand how UPDRS scores progress after initiation of symptomatic therapy and how this progression impacts sample size calculations. Methods We developed a non-linear model of UPDRS after introduction of symptomatic therapy. The model is specified as a non-linear mixed effects model and is applied to three different data sets from clinical trials. The model is then used to produce estimates for the change in UPDRS and its associated variance for a period of up to five years of follow-up. The estimates produced by the model serve as the basis for sample-size calculations for different lengths of follow-up (one through five years) and for different values of clinically meaningful change in UPDRS. Results Despite differences in the short-term benefit of the dopaminergic drugs, after a period of approximately six months UPDRS scores progress linearly at an estimated rate of approximately three points a year. The sample size that is required for a clinical trial where the baseline coincides with initiation of symptomatic therapy is very large. On the other hand, if baseline is set at six months after initiation of symptomatic therapy then the sample size required decreases with length of follow-up. Limitations Model specification and estimation is based on a set of simplifying assumptions regarding the progression of individual level UPDRS scores. Conclusions Sample size calculations based on these estimates indicate a substantial reduction in sample size if patients are required to be on symptomatic treatment for a period of time before being randomized to a neuroprotective trial.

Publisher

SAGE Publications

Subject

Pharmacology,General Medicine

Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3